Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07111247 · ClinicalTrials.gov registry record · Phase 4
Insights in Endocervical Mucus Secretion
A Phase 4 study of Cervical Mucus, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07111247: Recruiting Phase 4 study of Cervical Mucus, sponsored by Oregon Health and Science University.
NCT07111247 is a Phase 4 study of Cervical Mucus that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07111247, a Phase 4 study of Cervical Mucus, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.
Primary Outcome
Average cervical mucus scores at each study time point
Conditions Studied
Interventions
- DRUG Gonadotropin Releasing Hormone Antagonists Relugolix
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
What NCT07111247 shows while recruiting
NCT07111247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cervical Mucus appearing as the primary indexed condition, and to 1 intervention - of which Gonadotropin Releasing Hormone Antagonists Relugolix is the first listed.
NCT07111247 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT07111247 about?
NCT07111247 is a clinical study titled "Insights in Endocervical Mucus Secretion". Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.
What is the current status of trial NCT07111247?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2026-01-02. Estimated completion is 2027-08.
What conditions does trial NCT07111247 study?
This clinical trial studies the following conditions: Cervical Mucus.
What interventions are being tested in trial NCT07111247?
The interventions under investigation include: Gonadotropin Releasing Hormone Antagonists Relugolix (DRUG).
Who is sponsoring clinical trial NCT07111247?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07111247 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07111247's enrollment target sits among peer trials
15 1881st of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI